Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma

BACKGROUND: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facili...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biomark Res
Asıl Yazarlar: Kang, Liqing, Zhang, Jian, Li, Minghao, Xu, Nan, Qi, Wei, Tan, Jingwen, Lou, Xiaoyan, Yu, Zhou, Sun, Juanjuan, Wang, Zhenkun, Fu, Chengcheng, Tang, Xiaowen, Dai, Haiping, Chen, Jia, Wu, Depei, Yu, Lei
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222432/
https://ncbi.nlm.nih.gov/pubmed/32435496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00192-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller